A new treatment for one of the most aggressive and difficult-to-treat forms of breast cancer has received FDA approval, and for Black women — who face this disease at dramatically higher rates and with worse outcomes than other groups — the news represents a genuine step forward.
On June 24, the U.S. Food and Drug Administration approved Trodelvy, the brand name for sacituzumab govitecan-hziy, as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, known in medical shorthand as mTNBC. The approval was announced by the manufacturer, Gilead Sciences, and expands how the drug can be used, making it available not just as a later-line option but as the first treatment a patient receives after diagnosis.
Triple-negative breast cancer is the hardest form of the disease to treat because the cancer cells lack the three receptors — estrogen, progesterone, and HER2 — that most standard breast cancer therapies target. That absence of molecular hooks means fewer treatment options, more aggressive disease progression, and historically poorer survival outcomes. The FDA’s approval of Trodelvy both as a standalone treatment and in combination with immunotherapy drug pembrolizumab gives oncologists new tools earlier in the treatment timeline.
The stakes are especially high for Black women. According to healthcare advocates and published research, Black women are diagnosed with triple-negative breast cancer at approximately 2.3 times the rate of white women, often at younger ages and at more advanced stages, and experience a mortality rate that is 42 percent higher. The reasons are layered and well-documented: delayed access to screening and care, historical exclusion from clinical trials, the compounding health effects of chronic stress and systemic inequality, and longstanding gaps in how aggressively Black women’s symptoms are taken seriously in clinical settings.
The FDA’s approval was supported by Phase 3 clinical trial data from the ASCENT-03 and ASCENT-04 studies. “For people living with mTNBC, the first treatment choice can be pivotal, as many patients may not have the opportunity to receive subsequent therapies,” said Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and a principal investigator of the supporting trials. “This approval is heartening news for patients and the clinical community, and I believe offers a practice-changing first-line treatment option for all patients across PD-L1 status.”
Global regulatory submissions are underway, which means the approval in other countries could follow. For Black women in the United States dealing with a form of cancer the medical system has long been ill-equipped to address, the arrival of Trodelvy as a first-line option is meaningful news.
